Elena Nikulina

Day One Biopharmaceuticals advances front-line pLGG treatment with FIREFLY-2 enrollment milestone

Day One Biopharmaceuticals advances front-line pLGG treatment with FIREFLY-2 enrollment milestone
Day One Biopharmaceuticals enrolls FIREFLY-2 trial

Day One Biopharmaceuticals has announced the completion of patient enrollment for its FIREFLY-2 clinical trial, which is assessing a new front-line therapy for pediatric low-grade glioma (pLGG).

The company states that this achievement marks a significant step toward the evolution of pLGG treatment paradigms. Further updates from the trial, including results and potential regulatory pathways, are anticipated as Day One Biopharmaceuticals continues its efforts to establish an improved standard of care for children affected by this condition.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.